The U.S. Food and Drug Administration said on Friday it had granted traditional approval for AbbVie's (ABBV.N) "guided missile" cancer therapy, Elahere, for patients with a type of ovarian cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,